Disc arthroplasty pioneer and market leader, West Chester, Pennsylvania-based Centinel Spine announced that sales for the June quarter of 2024, not only set a record, but grew 26% year-over-year.
Centinel Spine Reports Record prodisc Sales for Q2
2 min read Premium comments
#centinelspine#prodiscSecondary
Driving the sales growth was, of course, the ever-expanding prodisc® portfolio of total disc replacement products and associated procedure instrumentation. To be clear, Centinel Spine, the market leader in total disc replacement products, not only set a sales record, but also outperformed its previous record quarter—which was Q1 of 2024!.
For the quarter ending June 30, 2024, Centinel Spine reported $22.1 million in worldwide prodisc total disc replacement revenue, representing a 26% year-over-year growth. The company also announced that worldwide prodisc cervical revenue grew 32% year-over-year to reach $14.6 million. U.S. sales for prodisc cervical disc rose 42% year-over-year growth.
Revenue was not the only area of growth, Centinel Spine also experienced an increase in surgeon use. Notable, per the press release, “record U.S. prodisc total surgeon user-base of nearly 600 surgeons, representing almost 40% YOY growth and sequential quarterly user growth of 10%.” This was the eighth consecutive quarter of surgeon user growth for the company.
Centinel Spine CEO Steve Murray commented, “The second quarter represents another record performance for Centinel Spine and these results demonstrate the continued strength behind our prodisc cervical and lumbar business in the rapidly expanding Total Disc Replacement market, worldwide.”
Murray continued, “The prodisc portfolio leads the Total Disc Replacement market in growth and has a long history of reliability and long-term performance. The new prodisc C Vivo and prodisc C SK Cervical System continues to excel, as exhibited by a rapidly expanding user base, record new users for the quarter, and strong repeat usage performance.”
In the third quarter 2022, the New Match-the-Disc™ prodisc C Vivo and prodisc C SK Cervical System had a limited U.S. release. Since that time, almost 7,000 procedures have been performed with the new system. Additionally, the company wrote “record prodisc C Vivo and prodisc C SK revenue in Q2 2024, representing nearly 67% and 100% YOY growth, respectively.”
In the second quarter of this year, according to the company, the number of surgeons using prodisc increased “nearly 140% YOY and almost 20% in sequential quarterly growth.”
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.